SCHEMBL2398532

SCHEMBL2398532

CN(C1CCN1C1=CC(=O)c2nc(-c3ccc(Br)cc3)oc2C1=O)C1CCN1C1=CC(=O)c2nc(-c3ccc(Br)cc3)oc2C1=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
USP1 O94782 2/20 0.32
USP19 O94966 2/20 0.32
UCHL3 P15374 1/20 0.32
WDR48 Q8TAF3 1/20 0.32
TP53 P04637 2/20 0.31
PKM P14618 1/20 0.31
MAPK1 P28482 1/20 0.31
PPARG P37231 1/20 0.31
NCOA2 Q15596 1/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
KDM4E B2RXH2 1/20 0.31
CDC25A P30304 1/20 0.31
CDC25B P30305 1/20 0.31
CDC25C P30307 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2404414 0.90 USP1 (0.44) USP1USP19UCHL3WDR48KDM4E
SCHEMBL2401752 0.88 RAB9A (0.36) MEN1KMT2AUSP1USP19WDR48
SCHEMBL2401248 0.88 NPSR1 (0.35) MEN1KMT2AUSP1USP19UCHL3
SCHEMBL2403259 0.82 TP53 (0.36) MEN1KMT2ATP53MAPK1NPC1
SCHEMBL2401601 0.79 CDC25A (0.55) USP1USP19UCHL3PKMKDM4E
SCHEMBL1916849 0.68 CDC25A (0.62) USP1USP19UCHL3WDR48MAPK1
SCHEMBL1918017 0.67 S100A4 (0.44) MEN1KMT2AMAPK1NPC1RAB9A
SCHEMBL2398528 0.67 CDC25A (0.50) USP1USP19UCHL3WDR48TP53
SCHEMBL5213585 0.65 NPC1 (0.45) MEN1KMT2AUSP1USP19UCHL3
SCHEMBL1918003 0.62 CDC25A (0.52) USP1USP19UCHL3WDR48MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US claimed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP claimed
US-8017637-B2 Inhibitors of cdc phosphatases IPSEN PHARMA S.A.S. (FR) 2011-09-13 US disclosed
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US disclosed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES CDC25C, CDC25A, CDC25B MEN1 1555/4885KMT2A 2264/4885USP1 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.